Results 241 to 250 of about 1,851,776 (356)

Distinct epigenomes in CD4⁺ T cells of newborns, middle-ages and centenarians. [PDF]

Sci Rep, 2016
Zhao M, Qin J, Yin H, Tan Y, Liao W, Liu Q, Luo S, He M, Liang G, Shi Y, Zhang Q, Cai W, Yin G, Zhou Y, Wang J, Li M, Huang Y, Liu A, Wu H, Zhang Z, Lu Q.   +20 more
europepmc   +1 more source

Orchidectomy of middle-aged rats decreases liver deiodinase 1 and pituitary deiodinase 2 activity [PDF]

, 2012
Branka Šošić‐Jurjević, Branko Filipović, Kostja Renko, Vladimir Ajdžanović, Milica Manojlović‐Stojanoski, Verica Milošević, Josef Köhrle   +6 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Polyphasic analysis of a middle ages coprolite microbiota, Belgium. [PDF]

PLoS One, 2014
Appelt S, Armougom F, Le Bailly M, Robert C, Drancourt M.   +4 more
europepmc   +1 more source

Short communication: Muscle protein synthetic response to microparticulated whey protein in middle-aged men [PDF]

, 2017
C.J. Mitchell, Randall F. D’Souza, Aaron C. Fanning, Sally D. Poppitt, David Cameron‐Smith   +4 more
openalex   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

[Urology in Upper Palatinate-what archeology, historical research, and historiography reveal : Part 1: from Roman Antiquity to the late Middle Ages]. [PDF]

Urologie
Otto W.
europepmc   +1 more source

Footprints of middle ages kingdoms are still visible in the contemporary surname structure of Spain. [PDF]

PLoS One, 2015
Rodríguez-Díaz R, Manni F, Blanco-Villegas MJ.   +2 more
europepmc   +1 more source

EFFECT OF EXERCISE TRAINING ON SERUM HIGH-SENSITIVITY C-REACTIVE PROTEIN CONCENTRATION IN HEALTHY MIDDLE-AGED AND ELDERLY SUBJECTS

, 2007
Ryuichi Ajisaka, Takumi Tanabe, Takeshi Otsuki, Haruka Murakami, Seiji Maeda, Kiyoji Tanaka, Hirohito Sone, Shinya Kuno   +7 more
openalex   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source